Zymergen Inc, a bio-based products developer, has filed Amendment No 2 to Form S-1 Registration Statement on April 14, 2021 with the U.S. Securities and Exchange Commission to announce terms for its IPO.
The company plans to raise $401 million by offering 13.6 million shares at a price range of $28 to $31. Assuming a successful IPO at the midpoint of the proposed price, the company expects a market capitalization of $3 billion.
The company creates new products with a proprietary platform that unlocks the design and manufacturing efficiency of biological processes with technology’s ability to rapidly iterate and control diverse functions.
The Emeryville, California-based company was founded in 2013 and booked $13 million in sales for the 12 months ended December 31, 2020. It plans to list on the Nasdaq under the symbol “ZY.” J.P. Morgan, Goldman Sachs, BofA Securities, Cowen, and UBS Investment Bank are underwriters of the IPO.
The company engages Freshfields Bruckhaus Deringer US LLP as US Securities Counsel, and Ernst & Young LLP as Independent Auditor.
#ipo #nasdaq #Zymergen #bio #product
Hexcellence Consulting has experienced IPO consulting team focus on listing in US Stock Market,
namely NYSE, Nasdaq and OTC Markets.
Should you interested to list your company in US Stock Market,
please contact us at [email protected]
